November 16, 2017 / 8:00 PM / a month ago

BRIEF-EGALET ANNOUNCES LATE-STAGE STUDY DATA ON EGALET-002

Nov 16 (Reuters) - Egalet Corp:

* EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 SAFETY STUDY EVALUATING SAFETY OF EGALET-002

* EGALET CORP - ‍EGALET-002 WAS GENERALLY WELL-TOLERATED​

* EGALET-PHASE 3 TRIAL EVALUATING SAFETY, EFFICACY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC PAIN IS EXPECTED TO BE COMPLETED BY YEAR END​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below